Autosomal recessive nonsyndromic deafness 12 is a genetic cause of hearing loss without other medical features. People with this condition typically have sensorineural hearing loss that is present from birth or early childhood and does not affect other organs. Hearing changes can range from mild to profound, and not everyone will have the same experience. Treatment focuses on hearing support such as hearing aids, cochlear implants, and speech and language therapy. Life expectancy is usually typical, and many living with Autosomal recessive nonsyndromic deafness 12 do well with early evaluation and support.
Overview
Autosomal recessive nonsyndromic deafness 12Symptoms
Autosomal recessive nonsyndromic deafness 12 causes bilateral hearing loss, often from birth or early childhood. Early signs of autosomal recessive nonsyndromic deafness 12 include not startling to loud sounds, delayed speech, and turning volume up. Other systems are typically unaffected.
Outlook and prognosis
Many living with Autosomal recessive nonsyndromic deafness 12 lead full, connected lives with the right supports. Early hearing aids, cochlear implants, and language access help speech, learning, and social development. Hearing typically remains stable; life expectancy is unaffected.
Causes and risk factors
Autosomal recessive nonsyndromic deafness 12 results from changes in the CDH23 gene, inherited in an autosomal recessive pattern from carrier parents. Risk rises with family history, parental relatedness, or founder variants. Loud noise or ototoxic drugs may worsen hearing.
Genetic influences
Genetics is central to Autosomal recessive nonsyndromic deafness 12. Two nonworking gene copies are needed, so parents are usually carriers without hearing loss. Variants in the GJB2 gene commonly cause it, and genetic testing guides diagnosis, carrier screening, and family planning.
Diagnosis
Diagnosis relies on clinical features of sensorineural hearing loss confirmed by audiology. Genetic tests identify causative variants; this genetic diagnosis of autosomal recessive nonsyndromic deafness 12 distinguishes it from other hearing disorders. Imaging may assess inner-ear structure.
Treatment and drugs
Treatment for autosomal recessive nonsyndromic deafness 12 focuses on better hearing and communication. Many benefit from newborn screening, early hearing aids or bone‑anchored devices, and—when appropriate—cochlear implants, plus speech‑language therapy. Ongoing audiology follow‑up and educational supports help at school and work.
Symptoms
In the first months, a baby may not startle to loud sounds or turn toward a parent’s voice. Autosomal recessive nonsyndromic deafness 12 typically shows up as hearing loss in both ears without other medical issues. Early features of autosomal recessive nonsyndromic deafness 12 usually appear in infancy or early childhood. Features vary from person to person and can change over time.
Many babies do not pass the routine newborn hearing screen. Follow-up tests check how the ear and hearing nerve respond and confirm the level of hearing loss.
Hearing loss affects both ears and can range from moderate to profound. In autosomal recessive nonsyndromic deafness 12, this is sensorineural, meaning the inner ear’s sound-sensing cells or signals are reduced.
Because less sound reaches the brain, children may start talking later or have unclear speech. This can make early learning and social play harder until communication support is in place.
Understanding speech is especially hard with background noise or when speakers are far away. People may rely more on lip reading, captions, or seeing the speaker’s face.
How people usually first notice Autosomal recessive nonsyndromic deafness 12?
Many families first notice Autosomal recessive nonsyndromic deafness 12 in early infancy when a baby doesn’t startle to sudden sounds, sleep through loud noises, or turn toward a parent’s voice the way most babies do. Newborn hearing screening—usually done within the first days of life—often flags reduced or absent hearing responses, prompting repeat testing and an audiology referral to confirm sensorineural hearing loss. These first signs of Autosomal recessive nonsyndromic deafness 12 are typically isolated to hearing, with no other physical differences, so early hearing tests and follow-up are key to recognizing it.
Types of Autosomal recessive nonsyndromic deafness 12
Autosomal recessive nonsyndromic deafness 12 is a genetic, non-syndromic form of hearing loss, so the key differences are in clinical variants rather than symptom clusters. Most people have stable, congenital hearing loss, but a minority experience hearing that worsens over time. Clinicians often describe them in these categories: stable congenital versus progressive forms. When people search for types of Autosomal recessive nonsyndromic deafness 12, they’re usually asking about these recognized clinical variants and how their hearing changes across childhood or adolescence.
Stable congenital
Hearing loss is present from birth and stays relatively steady over time. Many have moderate to severe loss that is consistent across both ears. Speech and language support early on can make a meaningful difference.
Progressive course
Hearing may be near normal or mild in early childhood, then gradually worsens over years. Some eventually move from moderate to severe or profound ranges, sometimes needing cochlear implants. The balance of symptoms can shift over time.
What genetics can tell you about symptoms
Some people with autosomal recessive nonsyndromic deafness 12 have changes in the GJB2 gene, which disrupts connexin 26, a protein that helps inner-ear cells share signals. This often causes stable, congenital sensorineural hearing loss, usually severe to profound, without other medical features.
Causes and risk factors
Autosomal recessive nonsyndromic deafness 12 is usually caused by inheriting two nonworking copies of the CDH23 gene. The main risk is when both parents are carriers, and the chance is higher with a family history or when parents are related. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t). You cannot change the genes passed down, but avoiding loud noise and certain ear-damaging medicines, like some antibiotics or chemotherapy, may help protect remaining hearing. Infections such as meningitis, premature birth complications, and repeated loud noise can worsen hearing over time, and families often ask about causes and risk factors for autosomal recessive nonsyndromic deafness 12.
Environmental and biological risk factors
Here’s what is known about environmental and biological risk factors for Autosomal recessive nonsyndromic deafness 12. Doctors often group risks into internal (biological) and external (environmental). Current research has not found outside exposures or pregnancy-related factors that reliably raise the chance of this specific condition occurring. The points below explain where links are not supported and how general hearing risks differ from the likelihood of this condition itself.
Advanced maternal or paternal age has not been shown to increase the chance of this condition. Age-related risks usually involve chromosome changes rather than this specific type of hearing loss.
Infections such as cytomegalovirus or rubella can cause hearing loss, but they have not been linked to a higher chance of this specific condition. Preventing infections still matters for overall fetal hearing health.
No known environmental exposures, including loud noise, solvents, or heavy metals, have been shown to increase the chance of Autosomal recessive nonsyndromic deafness 12. Such exposures can harm hearing generally, but they do not cause this specific condition.
Prematurity, low birth weight, or time in neonatal intensive care can raise the risk of hearing problems, but they do not increase the likelihood of Autosomal recessive nonsyndromic deafness 12. These factors tend to affect the ear after development rather than the underlying cause of this condition.
Genetic risk factors
Autosomal recessive nonsyndromic deafness 12 is most often linked to changes in a single gene, CDH23, which helps inner ear cells sense sound. People usually inherit one change from each parent, who typically hear normally but carry the gene. Risk can be higher in families or communities where the same change is common, or when parents are related. Risk is not destiny—it varies widely between individuals, and genetic testing for Autosomal recessive nonsyndromic deafness 12 can confirm the cause and clarify carrier status.
CDH23 changes: Harmful changes in the CDH23 gene disrupt tiny tip links on inner ear hair cells that turn sound vibrations into signals. When both copies of the gene are altered, hearing loss happens. This is the key known genetic cause of this condition.
Recessive inheritance: Two altered copies are needed—one inherited from each parent. People with only one altered copy are carriers and usually hear normally.
Carrier parents: If both parents carry a CDH23 change, each pregnancy has a 25% chance of a child with hearing loss. There is a 50% chance the child will be a carrier, and a 25% chance of inheriting no changes.
Family history: Having relatives with early-onset, sensorineural hearing loss raises the likelihood that CDH23 changes are present in the family. Patterns like siblings affected while parents hear normally fit a recessive cause.
Variant effect: Changes that leave some CDH23 function tend to cause nonsyndromic hearing loss. Changes that stop the protein early may cause a related syndrome that also affects vision, showing how the exact variant shapes outcomes.
Ancestry patterns: In some communities, a few CDH23 changes are more frequent because of founder effects. This can increase the chance that two carriers have children together.
Related parents: Parents who share recent ancestors are more likely to carry the same rare CDH23 change. This increases the chance their child inherits two altered copies.
Two different changes: Many people with this condition inherit two different CDH23 changes, one on each copy of the gene. The specific combination can influence severity and when hearing loss is first noticed.
Lifestyle risk factors
Lifestyle habits do not cause Autosomal recessive nonsyndromic deafness 12, but they can shape how symptoms are managed, whether residual hearing is preserved, and how well communication develops. Practical choices may reduce preventable hearing damage, listening fatigue, and device complications. Understanding how lifestyle affects Autosomal recessive nonsyndromic deafness 12 can help you prioritize what matters day to day.
Repeated loud sound (concerts, power tools, loud earbuds) can further damage any residual hearing. Using hearing protection and keeping volumes low helps preserve what hearing remains.
Tobacco smoke and nicotine reduce inner-ear blood flow and increase oxidative stress, which can worsen hearing thresholds and tinnitus. Quitting lowers the chance of accelerating hearing decline.
Binge or chronic heavy drinking is linked to poorer auditory processing and louder tinnitus, adding to communication strain. Limiting alcohol can reduce listening difficulty and sound sensitivity.
Nonessential use of ototoxic drugs (for example, high-dose aspirin/NSAIDs or certain aminoglycosides when avoidable) can further impair hearing. Discuss safer alternatives and dosing with your clinician before using these medicines.
Risk prevention
Autosomal recessive nonsyndromic deafness 12 is inherited, so you can’t fully prevent the condition itself after conception. Prevention focuses on planning before pregnancy, catching hearing differences early, and protecting any remaining hearing across life. Prevention is about lowering risk, not eliminating it completely. If you notice possible early symptoms of Autosomal recessive nonsyndromic deafness 12 in a baby—like not startling to loud sounds or not turning toward your voice—seek a hearing test promptly.
If hearing loss runs in your family or you belong to a community with known founder variants, ask about carrier testing before pregnancy. Finding out if both partners carry a change linked to autosomal recessive nonsyndromic deafness 12 can guide reproductive planning.
A genetics professional can explain inheritance, your chances in future pregnancies, and testing choices for you and relatives. Counseling also helps you plan for early hearing checks in future children.
Some families choose IVF with embryo testing or diagnostic testing during pregnancy to understand a baby’s risk. These are personal decisions that benefit from detailed counseling about benefits, limits, and timing.
Make sure your baby completes the hospital newborn hearing screen and follow-up if anything is unclear. Early confirmation opens the door to timely hearing support and language development.
Transmission
Autosomal recessive nonsyndromic deafness 12 is an inherited hearing condition, not an infection, so it can’t be “caught” or spread between people. It follows an autosomal recessive pattern: a child is affected only if they receive two non-working copies of the same gene—one from each parent. When both parents are healthy carriers, each pregnancy has a 25% chance the child will have the condition, a 50% chance the child will be a carrier like the parents, and a 25% chance the child will inherit neither non-working copy. If only one parent is a carrier, children may be carriers but usually will not have hearing loss from this condition. A genetics professional can explain how Autosomal recessive nonsyndromic deafness 12 is inherited in your family and discuss carrier testing.
When to test your genes
Consider genetic testing if you have early-onset hearing loss without other medical features, a family history of similar hearing loss, or relatives known to carry GJB2 (DFNB1) variants. Testing can confirm the cause, guide hearing care (including cochlear implant planning), and inform reproductive options. Newborns or infants who fail hearing screens also benefit from testing.
Diagnosis
Families often spot signs early, like a baby not startling to loud noises or a toddler who doesn’t turn when called. From there, hearing tests and a close look at family history help guide the next steps. Early and accurate diagnosis can help you plan ahead with confidence. The genetic diagnosis of Autosomal recessive nonsyndromic deafness 12 is confirmed with specific DNA testing after hearing tests show a pattern consistent with sensorineural loss without other medical features.
Hospitals use quick, painless checks soon after birth to flag possible hearing loss. If a baby does not pass, follow-up testing is arranged. This does not confirm the cause on its own.
Age-appropriate hearing tests measure how soft and which pitches can be heard. Results in this condition usually show sensorineural hearing loss in both ears. These tests help map severity and guide next steps.
A tiny ear probe measures echoes from the inner ear’s hair cells. Absent or reduced emissions suggest inner ear dysfunction. This supports sensorineural rather than conductive causes.
Small stickers on the head and soft clicks in the ear measure how the hearing nerve and brainstem respond. ABR helps confirm hearing loss in newborns and those who can’t do standard tests. It also estimates hearing levels for hearing device planning.
Stages of Autosomal recessive nonsyndromic deafness 12
Autosomal recessive nonsyndromic deafness 12 does not have defined progression stages. The hearing changes are usually present from birth or early childhood and are described by how severe they are and whether they stay stable or slowly progress, not by fixed “stages.” Different tests may be suggested to help confirm the diagnosis, including newborn hearing screening results, full hearing tests, an exam by an ear specialist, and sometimes genetic testing. Doctors also consider early symptoms of Autosomal recessive nonsyndromic deafness 12, like not startling to loud sounds, delayed babbling, or needing the TV volume turned up very high.
Outlook and prognosis
Families often want to know how life will change when a child is diagnosed with Autosomal recessive nonsyndromic deafness 12 (DFNB12), a genetic form of hearing loss that usually affects both ears from infancy or early childhood. Many living with DFNB12 develop strong communication skills with early support—hearing technology, sign language, or both—and participate fully in school, work, and community life. Mortality is not increased by DFNB12 itself; the condition affects hearing but not other organs, so life expectancy is typically the same as for people without hearing loss.
Prognosis refers to how a condition tends to change or stabilize over time. In DFNB12, hearing loss is usually stable to slowly progressive, but the pace varies by the exact gene change. Some people experience early profound loss, while others notice milder hearing changes that progress over years. Early care can make a real difference, especially during the first few years of language development. If hearing aids or cochlear implants are appropriate, outcomes are often best when fitted early and paired with consistent speech, auditory, and/or sign-language support.
Looking at the long-term picture can be helpful. Most children with DFNB12 attend mainstream schools with accommodations like captioning, FM systems, or note-taking support. As adults, many work across a wide range of fields; the main day-to-day adjustments involve communication access and noise management. The future may look uncertain now, but with a clear plan—regular audiology follow-up, timely technology updates, and language-rich environments—people with DFNB12 usually build confident communication and independent lives. Talk with your doctor about what your personal outlook might look like, including early symptoms of Autosomal recessive nonsyndromic deafness 12, expected hearing changes, and the best timing for interventions.
Long-term effects
Daily life with Autosomal recessive nonsyndromic deafness 12 mostly centers on how hearing loss shapes communication, learning, and social connection over the years. Long-term effects vary widely, and outcomes depend on the degree and course of hearing loss. Parents may notice early signs of autosomal recessive nonsyndromic deafness 12 in infancy, and the long-term picture typically focuses on hearing without other body systems being affected. Vision, balance, and overall health are usually normal, and life expectancy is expected to be typical.
Hearing loss is usually severe to profound from early life. In some, it stays stable, while in others it can slowly progress. Regular hearing checks help map the long-term pattern.
Spoken language may develop differently without early, consistent access to sound. Many with Autosomal recessive nonsyndromic deafness 12 build strong communication through spoken and/or signed language. School-age outcomes often reflect the timing and quality of auditory and language access.
Balance (vestibular) function is typically normal. Vision is not expected to be affected because this is a nonsyndromic condition. This contrasts with conditions that combine hearing loss with eye or balance issues.
School participation and later employment are generally expected to be typical when communication needs are met. People with Autosomal recessive nonsyndromic deafness 12 commonly pursue a full range of studies and careers. Long-term academic performance links closely with clear communication access in classrooms.
How is it to live with Autosomal recessive nonsyndromic deafness 12?
Living with autosomal recessive nonsyndromic deafness 12 often means growing up with stable, typically congenital hearing loss while the rest of health and development follow a typical path. Daily life can involve using hearing aids or cochlear implants, relying on visual cues, sign language, captioning, and thoughtful sound environments at school, work, and home. Many find strong community through Deaf culture or hard-of-hearing networks, and loved ones learn to support communication with clear face-to-face conversation, lighting, and consistent strategies. With early identification and accessible communication, people build rich social lives and careers, while families and friends become confident partners in reducing barriers.
Treatment and drugs
Treatment for autosomal recessive nonsyndromic deafness 12 focuses on improving hearing and communication, since the condition affects hearing only and not other parts of health. For many people, treatment begins with small daily steps, like consistent use of well-fitted hearing aids and practicing listening strategies in quiet settings. If hearing aids don’t provide enough benefit, cochlear implants may be considered; a specialist will discuss timing, expected outcomes, and rehabilitation, which includes regular programming and listening therapy. Beyond devices, speech-language therapy, classroom accommodations, captioning, and assistive listening systems (such as FM/DM systems) can help in school, work, and social life. Not every treatment works the same way for every person, so your doctor can help weigh the pros and cons of each option and adjust the plan over time.
Non-drug treatment
Living with Autosomal recessive nonsyndromic deafness 12 often centers on communication, learning, and daily safety rather than medicines. Non-drug treatments often lay the foundation for progress at home, school, and work. Recognizing early symptoms of Autosomal recessive nonsyndromic deafness 12 can help families start support sooner, which may improve speech and language outcomes. Plans are tailored to age, hearing levels, personal goals, and family preferences.
Newborn hearing screening and a full hearing test confirm the type and degree of hearing loss. Early referral to hearing services helps create a plan within the first months of life.
Custom-fitted devices amplify sounds when there is usable hearing. Regular adjustments keep settings matched to changes in hearing and growth.
For severe to profound loss, a surgically placed device can provide access to sound. Care includes a thorough evaluation, activation, and months of listening therapy.
Remote microphones, FM/DM systems, or Bluetooth stream speech directly to aids or implants in noisy places. These tools can make classroom lessons and meetings clearer.
Your genes may have an impact on how drugs work for you
Even when the hearing loss itself comes from two DFNB12 (PCDH15) gene changes, people can respond differently to supportive drugs or procedures because of other genes that affect drug handling. Variants in liver enzymes or inner-ear pathways can change benefit, side effects, or ideal dose.
Pharmacological treatments
Medicines do not restore hearing in Autosomal recessive nonsyndromic deafness 12, but they can help manage sudden changes or treat problems that temporarily worsen hearing, like ear infections. If early symptoms of Autosomal recessive nonsyndromic deafness 12 change suddenly—such as a rapid drop in hearing—doctors may use short-term treatments aimed at salvaging any recent loss. Sometimes medicines are taken short-term (acute treatment), while others are used long-term (maintenance therapy). Ask your doctor why a specific drug was recommended for you.
In sudden new hearing loss, a short course started as early as possible may help recover some recent loss. This does not cure Autosomal recessive nonsyndromic deafness 12 and is not helpful for long-standing stable hearing loss. Dosing is individualized and then tapered.
If a middle ear infection is present, antibiotics such as amoxicillin or amoxicillin–clavulanate can clear the infection and reduce muffled hearing. Treating infections does not treat Autosomal recessive nonsyndromic deafness 12 itself but can improve temporary setbacks.
Acetaminophen or ibuprofen can ease ear pain or discomfort during infections or after ear procedures. They do not change hearing levels in Autosomal recessive nonsyndromic deafness 12.
Genetic influences
Changes in a gene called CDH23 can disrupt how the inner ear senses sound, leading to hearing loss in some families. The autosomal recessive pattern means a child needs two gene changes—one from each parent—to develop Autosomal recessive nonsyndromic deafness 12. A “carrier” means you hold the gene change but may not show symptoms. When two carriers have a child, each pregnancy has a 25% chance (1 in 4) the child will have the condition, a 50% chance (1 in 2) the child will be a carrier, and a 25% chance of neither. The exact CDH23 changes matter: some cause hearing-only changes (nonsyndromic), while other changes in the same gene can cause a related condition called Usher syndrome that also affects vision or balance; genetic testing helps tell these apart. Severity and age at onset can vary—hearing may be very limited at birth or may decline over time—so results can help plan monitoring and support. Genetic testing for Autosomal recessive nonsyndromic deafness 12 can confirm the CDH23 changes and clarify which relatives might be carriers, and a genetics professional can explain what that means for your family.
Is Autosomal recessive nonsyndromic deafness 12 genetic?
Genetics is central to Autosomal recessive nonsyndromic deafness 12. Two nonworking gene copies are needed, so parents are usually carriers without hearing loss. Variants in the GJB2 gene commonly cause it, and genetic testing guides diagnosis, carrier screening, and family planning.
Pharmacogenetics—how genetics influence drug effects
For people with autosomal recessive nonsyndromic deafness 12, current care relies on hearing aids, cochlear implants, and communication therapy; there isn’t a medicine that reverses the hearing loss. Alongside medical history and hearing tests, genetic testing can help doctors choose and dose medicines more safely when treatment for other conditions is needed. A key example is a mitochondrial gene change (called MT‑RNR1) that greatly raises the risk of sudden, permanent hearing damage from certain hospital antibiotics called aminoglycosides; if this variant is found, teams try to avoid these drugs or use them only when truly lifesaving, with close hearing checks.
Some cancer medicines such as cisplatin can also harm the inner ear; while pharmacogenetic markers for cisplatin are still being studied, your baseline hearing status and any gene results may prompt extra protection strategies and frequent audiology monitoring. The specific CDH23 changes that cause this condition do not currently point to a particular medication, but they can inform timing of implants and expectations for benefit. Researchers are exploring gene- and RNA-based therapies, yet pharmacogenetic considerations in autosomal recessive nonsyndromic deafness 12 mostly focus on avoiding ototoxic drugs and tailoring monitoring, not on choosing a drug to restore hearing.
Interactions with other conditions
People with Autosomal recessive nonsyndromic deafness 12 usually have hearing-only involvement, so other organs aren’t typically affected, but real life can still bring overlaps. Ear conditions like recurrent middle ear infections or fluid behind the eardrum can add a temporary “conductive” layer on top of the inner-ear hearing loss, making listening and speech understanding even harder. A condition may “exacerbate” (make worse) symptoms of another, and that’s true here with ototoxic medications such as certain aminoglycline antibiotics or chemotherapy drugs, as well as loud-noise exposure, which can further reduce any remaining hearing. Because changes in the same gene can also cause Usher syndrome (hearing loss with vision problems), families sometimes get eye checks if there’s any uncertainty about the exact genetic changes or if night vision issues appear later on. Balance problems aren’t expected with this form of hearing loss, but if someone also has a separate vestibular disorder, fatigue and falls can increase, and hearing devices may need retuning in noisy settings. Interactions can look very different from person to person, so coordinated care with audiology, primary care, and—when relevant—ENT or ophthalmology helps catch issues early and protect hearing as much as possible.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns of children born with profound hearing loss in otherwise healthy families. Grandparents would recall two quiet cousins in the same generation, while most relatives heard normally. Before hearing screens or genetics, midwives and teachers were often the first to sense that a baby didn’t startle at loud sounds or a child didn’t develop speech at the usual pace.
From early theories to modern research, the story of autosomal recessive nonsyndromic deafness 12 has moved from careful observation to precise testing. Early medical notes grouped many types of hearing loss together, often focusing on visible ear problems or infections. Over time, descriptions became more nuanced, separating hearing loss that occurs on its own from loss that comes with other health conditions. This helped clinicians realize that some children had stable, sensorineural hearing loss from birth, with no other features, and that the pattern could run in families when both parents carried a silent gene change.
In recent decades, knowledge has built on a long tradition of observation. Newborn hearing screening showed that many babies have early, bilateral hearing loss even when pregnancy and birth were uncomplicated. As medical science evolved, researchers learned that different genes can lead to a similar outcome: significant hearing loss without other health issues. Within this group, autosomal recessive nonsyndromic deafness 12 emerged as one specific genetic form, defined by changes in a single gene and a consistent clinical picture.
Advances in genetics made confirmation possible rather than relying on family stories alone. Testing could show that parents with normal hearing each carried one copy of the gene change, while their child inherited two copies and had congenital hearing loss. This matched what earlier generations had noticed: the condition could appear unexpectedly in a family and affect boys and girls equally. Not every early description was complete, yet together they built the foundation of today’s knowledge.
With each decade, care has shifted from labeling to support and solutions. Earlier eras emphasized cause; modern care emphasizes communication access—such as hearing technology, sign language, and early therapy—guided by family preferences. Looking back helps explain why clear names and genetic testing matter today: they confirm the type of hearing loss, set realistic expectations, and connect families with others facing autosomal recessive nonsyndromic deafness 12.